Published in Gastroenterology on November 01, 2004
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int (2010) 5.02
Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology (2008) 4.26
Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol (2011) 3.36
Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol (2005) 1.87
Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant (2007) 1.70
Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl (2014) 1.54
Management of small hepatocellular carcinoma: a review of transplantation, resection, and ablation. Ann Surg Oncol (2010) 1.25
2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. Gut Liver (2015) 1.23
Live donors in liver transplantation. Gastroenterology (2008) 1.17
2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol (2015) 1.14
Outcomes of living and deceased donor liver transplant recipients with hepatocellular carcinoma: results of the A2ALL cohort. Am J Transplant (2012) 1.10
A pilot study of vasculogenic mimicry immunohistochemical expression in hepatocellular carcinoma. Arch Pathol Lab Med (2007) 1.09
Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World J Gastroenterol (2005) 1.03
The evolution of liver transplantation for hepatocellular carcinoma (past, present, and future). J Gastroenterol (2008) 0.95
Living-donor vs deceased-donor liver transplantation for patients with hepatocellular carcinoma. World J Hepatol (2014) 0.90
Liver transplantation for hepatocellular carcinoma. World J Gastroenterol (2009) 0.86
Management of hepatocellular carcinoma: Enlightening the gray zones. World J Hepatol (2013) 0.83
Tumor response to transcatheter arterial chemoembolization in recurrent hepatocellular carcinoma after living donor liver transplantation. Korean J Radiol (2007) 0.83
The stratifying value of Hangzhou criteria in liver transplantation for hepatocellular carcinoma. PLoS One (2014) 0.82
Update in management of hepatocellular carcinoma in Eastern population. World J Hepatol (2015) 0.81
Liver transplantation for hepatobiliary malignancies: a new era of "Transplant Oncology" has begun. Surg Today (2016) 0.81
Liver transplantation as a management of hepatocellular carcinoma. World J Hepatol (2015) 0.80
Historical perspective of living donor liver transplantation. World J Gastroenterol (2008) 0.79
Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol (2017) 0.78
Effect of the pringle maneuver on tumor recurrence of hepatocellular carcinoma after curative resection (EPTRH): a randomized, prospective, controlled multicenter trial. BMC Cancer (2012) 0.77
Impact of non-oncological factors on tumor recurrence after liver transplantation in hepatocellular carcinoma patients. World J Gastroenterol (2016) 0.77
Wait Time of < 6 and > 18 Months Predicts Hepatocellular Carcinoma Recurrence after Liver Transplantation: Proposing a Wait Time "Sweet Spot". Transplantation (2017) 0.76
Living Donor Liver Transplantation for Hepatocellular Carcinoma: It Is All about Donors? Int J Organ Transplant Med (2013) 0.75
Contemporary strategies in the management of hepatocellular carcinoma. HPB Surg (2012) 0.75
Liver transplantation for hepatocellular carcinoma from living-donor vs. deceased donor. Hepatobiliary Surg Nutr (2016) 0.75
Living vs. deceased-donor liver transplantation for patients with hepatocellular carcinoma. Transl Gastroenterol Hepatol (2016) 0.75
Smaller grafts do not imply early recurrence in recipients transplanted for hepatocellular carcinoma: A Chinese experience. Sci Rep (2016) 0.75
Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med (2013) 7.40
The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33
Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology (2009) 3.57
Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology (2008) 3.52
Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol (2009) 3.43
Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med (2012) 3.27
Evaluation of 300 minimally invasive liver resections at a single institution: less is more. Ann Surg (2007) 2.67
Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology (2010) 2.35
Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology (2014) 2.14
A comprehensive risk assessment of mortality following donation after cardiac death liver transplant - an analysis of the national registry. J Hepatol (2011) 1.94
Intrahepatic biliary cystadenoma: role of cyst fluid analysis and surgical management in the laparoscopic era. Surgery (2004) 1.89
Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA (2010) 1.84
Laparoscopic liver surgery: Shifting the management of liver tumors. Hepatology (2006) 1.58
Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl (2006) 1.56
Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients. Hepatology (2012) 1.56
Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl (2010) 1.56
Living kidney donor follow-up: state-of-the-art and future directions, conference summary and recommendations. Am J Transplant (2011) 1.51
Comparative effectiveness of liver transplant strategies for end-stage liver disease patients on renal replacement therapy. Liver Transpl (2014) 1.50
Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: durable chimerism predicts outcome. Transplantation (2013) 1.50
Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology (2009) 1.44
Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol (2010) 1.25
Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology (2011) 1.25
Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization. Cardiovasc Intervent Radiol (2009) 1.18
Dual-echo, chemical shift gradient-echo magnetic resonance imaging to quantify hepatic steatosis: Implications for living liver donation. Liver Transpl (2003) 1.12
Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol (2013) 1.08
The economic impact of MELD on liver transplant centers. Am J Transplant (2005) 1.05
Quality of life for donors after living donor liver transplantation: a review of the literature. Liver Transpl (2010) 0.98
A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl (2011) 0.97
Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis. J Hepatol (2012) 0.96
Laparoscopic liver resection. J Am Coll Surg (2005) 0.95
Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib. Hepatology (2013) 0.95
Genomic biomarkers correlate with HLA-identical renal transplant tolerance. J Am Soc Nephrol (2013) 0.94
Mortality in candidates waiting for combined liver-intestine transplants exceeds that for other candidates waiting for liver transplants. Liver Transpl (2003) 0.91
Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies: analyzing patterns of progression in 285 patients. Hepatology (2012) 0.91
Immunoregulatory profiles in liver transplant recipients on different immunosuppressive agents. Hum Immunol (2009) 0.91
Preoperative evaluation of the entire hepatic vasculature in living liver donors with use of contrast-enhanced MR angiography and true fast imaging with steady-state precession. J Vasc Interv Radiol (2003) 0.89
Should the liver transplant criteria for hepatocellular carcinoma be different for deceased donation and living donation? Liver Transpl (2011) 0.88
Donation after cardiac death liver transplantation: time for policy to catch up with practice. Liver Transpl (2012) 0.88
Renal ischemia/reperfusion injury activates the enhancer domain of the human cytomegalovirus major immediate early promoter. Am J Transplant (2005) 0.87
Biphasic recruitment of transcriptional repressors to the murine cytomegalovirus major immediate-early promoter during the course of infection in vivo. J Virol (2010) 0.87
Clinical Trials for Immunosuppression in Transplantation; The Case for Reform and Change in Direction. Transplantation (2017) 0.87
Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys (2010) 0.86
Transcriptional reactivation of murine cytomegalovirus ie gene expression by 5-aza-2'-deoxycytidine and trichostatin A in latently infected cells despite lack of methylation of the major immediate-early promoter. J Gen Virol (2007) 0.85
Bile duct injuries 12 years after the introduction of laparoscopic cholecystectomy. J Gastrointest Surg (2003) 0.85
Epigenetic control of cytomegalovirus latency and reactivation. Viruses (2013) 0.85
Aasld guidelines for the treatment of hepatocellular carcinoma. Hepatology (2017) 0.83
Intragraft TNF receptor signaling contributes to activation of innate and adaptive immunity in a renal allograft model. Transplantation (2009) 0.83
Hemodynamic evaluation before liver transplantation: insights into the portal hypertensive syndrome. J Clin Gastroenterol (2007) 0.82
Defining long-term outcomes with living donor liver transplantation in North America. Ann Surg (2015) 0.82
Impact of parenteral nutrition-associated liver disease on intestinal transplant waitlist dynamics. J Am Coll Surg (2007) 0.82
Frequency and significance of acute heart failure following liver transplantation. Am J Cardiol (2008) 0.81
Transplant tourism and unregulated black-market trafficking of organs. Am J Transplant (2009) 0.80
Treating and downstaging hepatocellular carcinoma in the caudate lobe with yttrium-90 radioembolization. Cardiovasc Intervent Radiol (2011) 0.80
ACE gene D/D genotype as a risk factor for chronic nephrotoxicity from calcineurin inhibitors in liver transplant recipients. Transplantation (2006) 0.79
Simulation modeling of the impact of proposed new simultaneous liver and kidney transplantation policies. Transplantation (2015) 0.78
TNF receptor independent activation of the cytomegalovirus major immediate early enhancer in response to transplantation. Transplantation (2008) 0.78
The renal benefit of mycophenolate mofetil after liver transplantation. Clin Transplant (2010) 0.78
HLA identical non-chimeric and HLA disparate chimeric renal transplant tolerance. Clin Transpl (2013) 0.78
Alemtuzumab induction in non-hepatitis C positive liver transplant recipients. Liver Transpl (2011) 0.77
TNF-alpha signaling is not required for in vivo transcriptional reactivation of latent murine cytomegalovirus. Transplantation (2009) 0.77
Mycophenolate mofetil monotherapy in liver transplant recipients. Clin Transplant (2011) 0.76
Making dollars and sense out of liver transplantation. Liver Transpl (2009) 0.76
Pretransplant Portal Vein Recanalization-Transjugular Intrahepatic Portosystemic Shunt in Patients With Complete Obliterative Portal Vein Thrombosis. Transplantation (2015) 0.76
Split liver sharing in the United States. Am J Transplant (2005) 0.75
Is antifibrinolytic drug use in liver transplantation associated with an increased risk of thromboembolic events? Nat Clin Pract Gastroenterol Hepatol (2007) 0.75
To kidney or not to kidney, when … is the question. Liver Transpl (2012) 0.75
Living donor liver transplant for malignancy. Transplantation (2005) 0.75
Biomarker Guidelines for High-Dimensional Genomic Studies in Transplantation: Adding Method to the Madness. Transplantation (2017) 0.75